Visitor Number: page counter

Click the Link to see our COVID-19 Pandemic Source Page
See the latest (slide presentation on COVID Antigen Testing CLICK HERE
Get information on vaccine efficacy in mix and match scenarios

Our Bimonthly Science Updates have Become MONTHLY -There is NEW information daily!
The October Update is available and a DRAFT of the November Update is now as well

Our October 2021 Update is now available:  CLICK HERE

Plus we have our new Supplemental  Science Presentations on Timely Topics 
Including these Links: 
 How we can Safely have School Openings (No.  6) (updated in August)
Want to try Ivermection?  This may eductate your decision:  Ivermectin 
Plus our Supplement on The Variants (No. 3) (updated 3/15/21)
and a treatise on COVID and the Endothelium (No. 7) (3/26/21)
and there are several other interesting topics! 

BRMoyer & Associates, LLC

any questions? e-mail us at:

Consultants in Drug and Biologics Development.   Focused areas of interest:  Applied Imaging Technologies, Pharmacokinetics, Radiobiology, Physical Toxicology (radiation, microwaves, energy exposures), Biodosimetry, Model Systems Development, and RegulatoryApproaches

A New Hampshire-based organization, our team has over 150 years in combined experience in developing nuclear medicine and MR contrast agent products and experience in developing medical countermeasures for pathologies related to radiation and chemical injury.  We have a wide background in the control of such exposures includes instrumentation, dermal, inhalation, and oral routes.  Radiation exposure dosimetry, sources, and assessments of internal contamination are from year of  academic and biotechnology industry research. 

Our Goals are Your Goals:  We can aid in your quest for animal models of disease, toxicology and efficacy studies, analytical testing processes, statistical assessments, PK/PD/TK analyses, process development and manufacturing, pre-clinical and clinical protocol designs, subcontractor site visits and FDA submissions: 
Our diverse backgrounds and broad industry contacts allows us to bring the expertise that is needed to specific problem solving opportunities in the diverse biotechnology fields.

Mr Moyer's Expertise: Mr Moyer is currently a Sr Scientific Advisor for CBRN medical countermeasures and radiation dosimetry in mass casualty chemical and radiation events (IND, RDD and RED) for BARDA (HHS/ASPR, US Gov; Biomedical Advanced Research and Development Authority, Washington, DC; retired from full time contractor activities in July 2016 and brought back in July 2017). Mr Moyer has also been conferred Emeritus status by the Nuclear Medicine Technology Certification Board in 2017. 


He is a Clinical Pharmacologist who has specialized in the development and clinical uses for imaging agents in both nuclear (PET/SPECT) and MRI (Gd, Mn and Dy). A specialist in PK/PD analysis and models of disease he has worked in the fields of infection/sepsis, vascular, hematopoietic, neurologic, gastrointestinal, renal, hepatic, pulmonary, and bone pain. Significant participation in the approvals of 8 drug NDAs and 3 BLAs and other product experience with Mabs, Nabs, cell therapies, recombinant proteins, peptides and glycan drug development.

Consultant services options:  Mr. Moyer has been contracted by HHS/BARDA as a Special Government Employee/ Consultant/ SME Sr Science Advisor for the radiation medical countermeasures group which prohibits his participation as a consult or to work on projects for or involving BARDA or the US Government.   This work assignment will preclude any medical countermeasure development work related to the BARDA portfolio ( until his service period has ended.  All other development work where we may be able to assist you, is welcomed.  


Please contact us using our Contact Page if you have any questions or request for services.  

Mr Moyer is the former Chair of the AAPS Pharmaco-Imaging Focus Group (2013-14) and served as the Editor of the  PIFG Newsletter.

Go to our Menu bar and click on the PIFG pages to see past Newsletter issues

A new update (June 2021) on radiation injury and the endothelium is available as a Part 1 and Part 2 package.  The concept was to identify the Endothelium as a multitude of different targets susceptible to reactive oxygen speices (ROS) and reactive nitrogen species (NOS).;  The endothelium is a complex of pharmacologic mechanisms that all interplay for a target tissue that literally is connected intimately with every fucntional system in the body.  Emphasis on vascular functions, coagulopathies and nuclear signaling processes is provided. 

Part 1 Click HERE  ~~~~~  Part 2 Click HERE